Many clinicians consider carboplatin monotherapy in advanced castrate-resistant prostate cancer (CRPC) patients who have progressed through all available hormonal and standard chemotherapy treatment options, despite the limited evidence to justify its use. This retrospective analysis aimed to evaluate the use of carboplatin monotherapy in patients with refractory prostate cancer in Australia. Efficacy (PSA response, duration, and survival) as well as toxicity was evaluated. Demographic data, PSA response rates, survival data and details of carboplatin treatment protocols, including dose and duration, were collected. Exploratory analyses were conducted on potential prognostic factors. Fifty-one patients received carboplatin: median age 68 (range 55-86 years). Most patients (78.3%) received carboplatin AUC 5 at 3-week intervals. The median number of cycles of carboplatin received was 3 (range 1-17). The median duration of treatment was 63 days (range 1-441). The median overall survival was 6.8 months. Six (11.8%) patients had a PSA response ≥ 50%. The median time to PSA progression on carboplatin, as defined by PCWG, was 67 days (range 15-418). Sixteen patients (31%) required dose delays or reductions and 8 patients (15.6%) ceased carboplatin due to treatment toxicity. Carboplatin is often used in Australia once all available standard treatment options have been exhausted in patients with CRPC. Toxicity is mild, and a minority of patients have responses, but these responses are rarely durable.

中文翻译：

---

卡铂治疗转移性去势抵抗性前列腺癌：对经过大量预处理的患者进行的回顾性研究 (COMPACT)

许多临床医生考虑对晚期去势抵抗性前列腺癌 (CRPC) 患者进行卡铂单药治疗，这些患者已通过所有可用的激素和标准化疗方案取得进展，尽管证明其使用合理性的证据有限。这项回顾性分析旨在评估卡铂单一疗法在澳大利亚难治性前列腺癌患者中的使用情况。评估疗效（PSA 反应、持续时间和存活率）以及毒性。收集人口统计数据、PSA 反应率、生存数据和卡铂治疗方案的详细信息，包括剂量和持续时间。对潜在的预后因素进行了探索性分析。 51 名患者接受卡铂治疗：中位年龄 68 岁（范围 55-86 岁）。大多数患者 (78.3%) 每 3 周接受一次卡铂 AUC 5。接受的卡铂周期中位数为 3 个（范围 1-17）。中位治疗持续时间为 63 天（范围 1-441）。中位总生存期为 6.8 个月。六名 (11.8%) 患者的 PSA 反应≥ 50%。根据 PCWG 的定义，卡铂治疗后 PSA 进展的中位时间为 67 天（范围 15-418）。 16 名患者 (31%) 需要延迟或减少剂量，8 名患者 (15.6%) 由于治疗毒性而停止使用卡铂。在澳大利亚，当 CRPC 患者用尽所有可用的标准治疗方案后，通常会使用卡铂。毒性较轻，少数患者有反应，但这些反应很少能持久。